AI
By
Can Personalis and Tempus Leverage AI to Transform Cancer Recurrence Detection for 150,000 Colorectal Patients? Strategic Expansion Deepens MRD Leadership
Key Highlights AI at the Core of Next-Gen Recurrence MonitoringThe expansion of Personalis’ NeXT Personal® MRD test into…
Will AI-Powered Querent™ by Mango Sciences Transform Veeda Lifesciences’ Global Clinical Trial Efficiency?
Key Highlights AI-Driven Precision in Global Trial RecruitmentVeeda Lifesciences, a global CRO, has announced a strategic investment in…
Can Revolution Medicines and Iambic’s AI Alliance Accelerate the Discovery of Next-Gen Cancer Drugs Targeting RAS Mutations?
Key Highlights AI-Powered Discovery for RAS-Addicted CancersRevolution Medicines, a leader in targeting RAS-driven cancers, is turning to artificial…
Can Johnson & Johnson’s 6-Point AI Strategy Revolutionize Surgery, Drug Discovery, and Global Patient Care?
Key Highlights From Experimentation to Execution: Focused AI for Measurable OutcomesAfter piloting 900+ generative AI use cases, Johnson…
Can XtalPi & DoveTree’s $6 Billion AI Partnership Transform “Undruggable” Disease Targets in Biopharma – The Dawn of Robotics-Driven R&D at Scale?
Key Highlights: Strategic Overview: Industry’s Largest AI-Pharma CollaborationThis collaboration—one of the biggest in AI-driven drug discovery—combines XtalPi’s robust…
Can Harvard’s FaceAge and Emerging AI Facial Recognition Apps Revolutionize Disease Prediction and Personalized Care in Biopharma and Healthcare?
Key Highlights: AI Facial Recognition as a Medical BiomarkerDeveloped at Harvard Medical School, the FaceAge algorithm analyzes photos…
